rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANAB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AnaptysBio at UBS Global Biopharma Conference 2026: Royalty growth, legal risk
      Nov 17Investing.comANABUBS
      AnaptysBio earnings beat by $0.75, revenue topped estimates
      Nov 13Investing.comANAB
      AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
      Nov 12Yahoo FinanceANAB
      Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceANAB
      AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
      Oct 31Yahoo FinanceANAB
      Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?
      Oct 30Yahoo FinanceANAB
      AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
      Oct 20Seeking AlphaANABGSK
      AnaptysBio, GSK gain FDA label expansion for Jemperli (ANAB)
      Oct 19Seeking AlphaANABGSK
      AnaptysBio: Fully Valued — With Major Litigation Uncertainty (NASDAQ:ANAB)
      Oct 13Seeking AlphaANAB
      Anaptysbio director Renton Hollings sells $249,371 of shares
      Oct 13Investing.comANAB
      Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed

      First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.

      Oct 12Investor's Business DailyANAB
      AnaptysBio earnings beat by $5.58, revenue topped estimates
      Oct 10Investing.comANAB
      AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story

      AnaptysBio (ANAB) has drawn fresh attention after recent trading left the stock down about 18% over the past month and roughly 30% over the past 3 months. That slump now frames how investors assess its royalty driven biotech model. Short term momentum for AnaptysBio has clearly cooled, with the share price down 18.4% over 30 days and 30.4% over 3 months. However, the 1 year total shareholder return of 118.2% and 3 year total shareholder return above 2.7x show a very different longer term...

      Oct 9Yahoo FinanceANAB
      AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance

      AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to US$6.06 for the quarter and US$6.09 for the six months. A key driver of the very large reported profit was a US$181.5 million income-tax benefit from releasing a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an...

      Sep 26Yahoo FinanceANAB
      AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

      AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit. The tax adjustment reflects greater expected use of tax assets following […]

      Sep 26Yahoo FinanceANAB
      Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailANAB
      AnaptysBio earnings analysis: questions answered and next catalysts
      Sep 22Investing.comANAB
      AnaptysBio (ANAB) Gets a Buy from Leerink Partners

      Detailed price information for Anaptysbio Inc (ANAB-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailANAB
      Why is AnaptysBio stock rising afterhours today?
      Sep 22Investing.comANAB
      AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

      AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

      Sep 21Yahoo FinanceANAB
      AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

      AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the l

      Sep 21Yahoo FinanceANAB
      Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

      Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionLitigation with GSK and Tesaro: trial held

      Sep 21Yahoo FinanceANAB
      AnaptysBio earnings missed by $0.34, revenue fell short of estimates
      Sep 12Investing.comANAB
      AnaptysBio earnings on deck: Jemperli lawsuit takes center stage
      Sep 10Investing.comANAB
      Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

      Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund’s Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As of June 30, 2026, the top ten positions comprised approximately 72% of the portfolio, and the portfolio held approximately […]

      Sep 9Yahoo FinanceANAB
      Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

      SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET. A live webcast of the presentation will be available on the investor section of the

      Sep 1Yahoo FinanceANAB
      AnaptysBio stock rating maintained at Outperform by Wolfe Research
      Aug 31Investing.comANAB
      AnaptysBio earnings on deck: Can Jemperli offset revenue slide?
      Aug 30Investing.comANAB
      TD Cowen lowers Anaptysbio stock price target to $70 on FDA review
      Aug 25Investing.comANAB

      This is the newest page. Registered accounts read further back.